Glucotrack Closes Reverse Merger with Lokahi Therapeutics, Locks in $4.45M Bridge Financing, and Opens a $50M Equity Line
GCTK sits 90% above its 52-week low of $0.291 on elevated volume (11× avg).
Summary
Glucotrack closed a reverse merger with Lokahi Therapeutics, handing Lokahi 90% control, and secured $4.45M in bridge financing plus a $50M equity line. The CEO was replaced, and the company believes it has regained Nasdaq compliance.
Key Events · M&A and Partnerships · GCTK
-
Reverse Merger with Lokahi Therapeutics
Lokahi securityholders received 19.99% of Glucotrack common stock and Series A preferred convertible into 90% of the combined company on a fully diluted basis, effectively taking control.
-
$4.45M Bridge Financing
The company issued senior secured convertible notes with a 22% original issue discount, 8% interest, 9-month maturity, and warrants covering 125% of the principal amount. The notes are convertible at a variable price tied to the stock's VWAP.
-
$50M Equity Line of Credit
A Common Stock Purchase Agreement with White Lion Capital allows the company to sell up to $50M of common stock over three years at a discount to market, with a $1M commitment fee and a $10M commitment warrant.
-
CEO and Management Change
Paul Goode stepped down as CEO and was replaced by Erik Emerson, formerly CEO of Lokahi. Goode will serve as CTO of the combined company and CEO of the CBGM subsidiary.
Analysis · GCTK · Industrial Applications And Services
In a deal that effectively hands control to Lokahi Therapeutics, Glucotrack has been acquired through a reverse merger that gives Lokahi securityholders 90% of the combined company on a fully diluted basis. The transaction is backed by a $4.45 million bridge loan carrying a 22% original issue discount and warrants, as well as a $50 million equity line of credit with White Lion Capital. A leadership overhaul accompanied the closing, with the CEO replaced, and management believes the company has now regained compliance with Nasdaq's minimum equity requirement. For a business that was staring down delisting and going-concern warnings, this represents a complete reset — new control, fresh capital, and a different business model. The bridge financing terms are aggressive, and the equity line could lead to significant dilution if drawn, but the immediate survival risk appears reduced.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCTK was trading at $0.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.29 to $14.14. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.